Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10530149				
Filing Date		2005-09-29				
First Named Inventor	Herbe	nt BOERNER, ET AL				
Art Unit		2671				
Examiner Name						
Attorney Docket Number		DE020219				

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	late	Name of Patentee or Applicant of cited Document		Releva		Lines where ges or Relev	
	1	5003221		1991-03	-26	SHIMIZU					
	2	5804918		2007-03	-15	YONEKAWA, ET AL					
	3	6019654		2000-02	-01	кім					
	4	6117529		2000-09	-12	LEISING ET A	r				
If you wish	h to a	d additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant of cited Document		Releva		Lines when ges or Relev	
	1										
If you wis	n to a	d additional U.S. Publi:	shed An	plication	citation	information o	lease click the Ad	d button	Add		_
FOREIGN PATENT DOCUMENTS Remove											
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	here Rel	or Relevant	TS

U.S.PATENTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10530149			
Filing Date		2005-09-29			
First Named Inventor Herbe		art BOERNER, ET AL			
Art Unit		2671			
Examiner Name					
Manager Davids North		DE020240			

	1	0272760	EP	A1	1988-06-29	KPENV			
	2	1041861	EP	A1	2000-10-04	SEIKO CORP			
	3	10009931	DE	A1	2000-09-07	NISSAN CO. LTD			
	4	2341486	GB	A	2000-03-15	FUJI CO LTD			
	5	0012226	wo	A1	2000-03-09	FED CORP			
	6	2000182780	JP	A	2000-06-30	FWI CO LTD			
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	lease click the Add butto	n Add		
NON-PATENT LITERATURE DOCUMENTS Remove									
Examiner Initials*	Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								
	1								

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10530149	
	Filing Date		2005-09-29	
	First Named Inventor Herbe		ert BOERNER, ET AL	
	Art Unit		2671	
	Examiner Name			
	Attorney Docket Numb	er	DE020219	

See find. Codes of USPTO Planto Tocuments at view, USPTO, DOV or MFEP 901.04. * Enter office that its such the document, by the two-later code, VIPO Standard ST3.3. ** Frequence painted consenset, the inclusion on the year of the reigny of the Engeror manter proceed the sensel number of the painted consumer. **
**Incl of Coursent by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. **
**Applicant is to place a cheek or many them is proceed to the painted consumer to the painted consumer

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10530149			
Filing Date		2005-09-29			
First Named Inventor	Herbert BOERNER, ET AL				
Art Unit		2671			
Examiner Name					
Attorney Docket Number		DE020219			

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 97 CFF 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(4)(c).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Eric M. Bram/	Date (YYYY-MM-DD)	2007-03-27
Name/Print	Eric M. Bram	Registration Number	37 285

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.